Schizophrenia News and Research

Latest Schizophrenia News and Research

Johns Hopkins scientists develop mouse model for autism spectrum disorders

In an effort to unravel the tangled biology of autism, Johns Hopkins scientists have created a mouse model that mimics a human mutation of a gene known to be associated with autism spectrum disorders.

21 Jun 2011

Study: Dyslexia gene controls cilia in brain neurons

Scientists at Karolinska Institutet in Sweden have discovered that a gene linked to dyslexia has a surprising biological function: it controls cilia, the antenna-like projections that cells use to communicate.

20 Jun 2011

Risperidone recall by J&J

Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, recalled about 16,000 bottles of its Risperdal schizophrenia drug on reports of an uncharacteristic odor. The recall affects one lot that was shipped between Aug. 27, 2010, and Feb. 15, 2011.

19 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

Life Technologies introduces CytoTune-iPS Reprogramming Kit

Life Technologies Corporation today announced the launch of CytoTune-iPS Reprogramming Kit -- research technology that provides far improved efficiency over standard methods to develop induced pluripotent stem cells from human somatic cells.

16 Jun 2011

Brain research funds crisis: Report

According to the European College of Neuropsychopharmacology there is a dramatic drop in private and public funding for research in brain diseases that has led to a “withdrawal of hope” for millions of sufferers and could delay the search for treatments and cures by 30 years.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Study: Early intervention can reduce recurrences, prevent psychosis

Schizophrenia is a chronic illness that most often comes on in late adolescence or young adulthood and can devastate patients' lives. Many physicians and researchers believe that early intervention can increase the chances for recovery, reduce recurrences and even prevent the warning signs of psychosis from progressing to the actual disease.

15 Jun 2011

Newborn neurons help create emotional context of memory

Fear burns memories into our brain, and new research by University of California, Berkeley, neuroscientists explains how.

15 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Survey reveals increase in drinking, cannabis use and psychological distress

The latest survey of Ontario adults from the Centre for Addiction and Mental Health (CAMH) shows increasing rates of daily drinking and cannabis use and high levels of psychological distress. The results of the 2009 CAMH Monitor survey, the longest running survey tracking mental health and addiction indicators among adults in Ontario, were published today.

13 Jun 2011

Servier, Cortex sign new option agreement for AMPAKINE technology

Cortex Pharmaceuticals, Inc. entered into a new agreement with Servier to sell its remaining rights to the jointly discovered high impact AMPAKINE compound, CX1632.

13 Jun 2011

Smoking keeps weight off: Study finds out how

The researchers have found that nicotine activates a pathway in the brain that suppresses appetite. The study was published in the journal Science. The authors believe this discovery should lead to better diet drugs.

9 Jun 2011

Study examines how stigma affects self-concept, identity of individuals with mental illness

A new study led by a Northern Illinois University sociologist shows that while family members often provide critical support, they also can sometimes be the source of stigmatizing attitudes that impede the recovery of mentally ill relatives.

8 Jun 2011

New neurons may take over six months to mature

New neurons take more than six months to mature in adult monkeys and that time is likely even longer in humans, according to researchers at the University of Pittsburgh School of Medicine, the University of Illinois, and Pennsylvania State University.

8 Jun 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

Viewpoints: Confronting 'giant' Medicare choices; first lady's anti-obesity campaign; Calif. insurance rules

Sometimes life presents you with a basic philosophical choice. Americans are going to have to confront a giant one over the next several years. It starts in the wonky world of Medicare. ... Democrats have much greater faith in centralized expertise. ... [Republicans] have much greater faith in the decentralized discovery process of the market.

8 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

'Switching off' critical disease causing gene can reestablish Rett syndrome in adult animals

An IRSF funded study published today in the journal Science has shown that the childhood disorder Rett syndrome, can be reestablished in adult animals by "switching off" a critical disease causing gene in healthy adult animals.

3 Jun 2011

New genomics research on abnormal brain development

Local researchers are finally on the road to developing targeted treatments for serious, life-long disabilities such as autism and schizophrenia, thanks to new genomics research focusing on abnormal brain development.

27 May 2011